Amneal Pharmaceuticals, Inc. (AMRX) Stock: Price, Forecast & Analyst Target
Amneal Pharmaceuticals, Inc. (AMRX) — MoonshotScore 68/100 (Strong band), calculated Nov 22, 2026. Price $21.12 (-1.26%), as of the Nov 20, 2026 trading session; market cap $7.36B. Expected results Feb 26, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 46.76× (market value Nov 17, 2026; cash Sep 30, 2026) · expected results Feb 26, 2027
Amneal Pharmaceuticals, Inc. · AMRX · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-13: Amneal manufactures generic and branded pharmaceuticals across divisions serving wholesalers, specialty channels, and the government. A turnaround from near-break-even to robust profitability in recent quarters raises a central question: can the improvement hold despite mounting debt?
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Amneal Pharmaceuticals (AMRX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 1.96 · Piotroski F 5
- ROE 70.0% · ROA 7.5% · current ratio 1.87
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 71 | Strong | |
| 69 | Strong | |
| 69 | Strong | |
| 66 | Strong | |
| 66 | Strong | |
| 66 | Strong |
The score moved from 66 in the stored Nov 21, 2026 snapshot to 68 in the current publication computed Nov 22, 2026 (+2); the largest pillar moves were Momentum +2. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $21.12 | |
| Change on the day | -1.26% | |
| 52-week range | $11.39–$22.07 | |
| Market capitalisation | $7.36B | |
| Price / earnings (trailing) | 49.12 | |
| Shares traded on the day | 1.67M | |
| Beta (volatility vs the S&P 500) | 1.25 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
On other two strengths, 60 mg and 90 mg, our post-approval supplement is ready, and we will be filing both the strengths in this quarter and expect the launch in the second half of next year.
Chintu Patel · Statement from
We expect to launch in second half next year, towards late.
Chirag Patel · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Amneal Pharmaceuticals (AMRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Amneal Pharmaceuticals (AMRX), and what does it report?
Short answer · as of
Generics are commodity sales through wholesale channels where Amneal competes on manufacturing scale and cost.
Research dated 2026-09-13.
But Specialty products—Rytary for Parkinson's, Unithroid for hypothyroidism—command premium pricing where brand and efficacy matter more than cost. AvKARE extends into long-term government contracts, creating a stickier revenue base. The income statement reflects this mix: gross margin expanded despite flat revenue, suggesting product mix favoring branded and contract sales.
What do the latest results show for Amneal Pharmaceuticals (AMRX)?
Research dated 2026-09-13.
Recent quarters accelerated earnings per share and expanded operating margins substantially. The mechanism appears to be volume recovery in Generics following supply-chain normalization and a full period of contribution from prior Specialty acquisitions. AvKARE maintained steady contract revenues. The pace of improvement suggests demand tailwinds, though management guidance restraint signals caution about durability.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $862.68M Sep 30, 2026
- Latest quarter · R&D
- $68.37M Sep 30, 2026
- Latest quarter · SG&A
- $139.65M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $95.42M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $862.68M | $68.37M | $139.65M | $95.42M |
| Jun 30, 2026 | $796.20M | $41.10M | $148.72M | $145.98M |
| Mar 31, 2026 | $722.52M | $38.38M | $138.86M | $142.87M |
| Dec 31, 2025 | $814.32M | $34.82M | $146.46M | $114.50M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $862.68M Nov 3, 2026
- Latest report · revenue estimate
- $817.77M Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $862.68M | $817.77M | $0.2600 | $0.2374 |
| Jul 30, 2026 | $796.20M | $768.21M | $0.3000 | $0.2225 |
| May 7, 2026 | $722.52M | $719.66M | $0.2700 | $0.1700 |
| Feb 27, 2026 | $814.32M | $807.35M | $0.2100 | $0.1800 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $785M | $2M | $0.01 (diluted) |
| Q4 FY2025 | $814M | $35M | $0.11 (diluted) |
| Q1 FY2026 | $723M | $62M | $0.19 (diluted) |
| Q2 FY2026 | $796M | $58M | $0.18 (diluted) |
What are the financial strengths and risks for Amneal Pharmaceuticals (AMRX)?
Short answer · as of
Cash and short-term investments were $157.40M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $100.28M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash position deteriorated despite operational profitability—working capital swings and heavy capex consumed what should have been strong free cash. Debt substantially exceeds available cash, placing debt service ahead of strategic investment or shareholder returns. Refinancing risk is manageable near-term but credit cost constrains margin. A ratings downgrade would be a sharp reset to competitive position.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 49.12 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $100.28M Sep 30, 2026
- Previous quarter · operating cash flow
- −$19.26M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $100.28M | −$39.58M |
| Jun 30, 2026 | −$19.26M | −$45.59M |
| Mar 31, 2026 | −$28.72M | −$13.86M |
| Dec 31, 2025 | $130.32M | −$43.17M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Amneal Pharmaceuticals (AMRX)?
Short answer · as of
The next earnings report is expected on Feb 26, 2027.
Research dated 2026-09-13.
Watch debt covenant compliance and near-term refinancing terms as leverage climbs. Generics volume could reverse if supply recovery saturates or competitors cut prices sharply—margin compression would force infrastructure costs down. Monitor Specialty uptake against management guidance and whether AvKARE contract renewals hold steady.
What management is planning
How does Amneal Pharmaceuticals compare with its peers?
Short answer
Amneal Pharmaceuticals's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Against larger generics specialists, Amneal's Specialty and government segments differentiate—but smaller scale versus integrated peers means higher financing costs and less R&D cushion. Against pure-Specialty players, it carries commodity exposure. The hybrid model avoids the margin floor of pure Generics yet lacks the pricing power of pure-play branded. It is defensible but not dominant.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.10 Nov 20, 2026 | $6.68B | 96 5-pillar Nov 22, 2026 | |
| $68.55 Nov 20, 2026 | $1.56B | 94 5-pillar Nov 22, 2026 | |
| $79.11 Nov 20, 2026 | $32.1B | 87 5-pillar Nov 22, 2026 | |
| $22.91 Nov 20, 2026 | $3.67B | 82 5-pillar Nov 22, 2026 | |
| $14.89 Nov 20, 2026 | $12.4B | 79 5-pillar Nov 22, 2026 | |
| $28.61 Nov 20, 2026 | $5.94B | 75 5-pillar Nov 22, 2026 | |
| $13.22 Nov 20, 2026 | $2.39B | 71 5-pillar Nov 22, 2026 | |
| Amneal Pharmaceuticals (AMRX) — this page | $21.12 | $7.36B | 68 |
| $4.18 Nov 20, 2026 | $2.07B | 48 5-pillar Nov 22, 2026 | |
| $8.37 Nov 20, 2026 | $2.84B | 40 5-pillar Nov 22, 2026 | |
| $25.74 Nov 20, 2026 | $12.9B | 36 5-pillar Nov 22, 2026 | |
| $19.63 Nov 20, 2026 | $22.5B | 35 5-pillar Nov 22, 2026 | |
| $8.22 Nov 20, 2026 | $3.08B | 30 5-pillar Nov 22, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $20.00 – $27.00
- Consensus target
- $23.43
- Median target
- $24.00
Consensus record · Captured .
Measured against a quoted price of $21.12 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 17, 2026
- Transactions
- 15
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 4
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 53.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 50.3% Prior to period end Sep 30, 2026
- Reporting holders
- 338 Period end Sep 30, 2026
- Previous quarter · holders
- 315 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 26,877,188 |
| Vanguard Portfolio Management LLC | 12,365,663 |
| Tpg Gp A, LLC | 12,328,767 |
| Rubric Capital Management LP | 8,536,755 |
| Vanguard Capital Management LLC | 7,987,664 |
Tracked investors
Which of the 16 named investors we follow held AMRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AMRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About AMRX (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is AvKARE and why does Amneal own it?
AvKARE serves government buyers—DoD and Veterans Affairs—with bulk pharmaceuticals and medical supplies under long-term contracts. It is a sticky, contract-based business insulated from wholesale commodity pricing. Revenue is stable and predictable, providing portfolio diversification.
Does Amneal have blockbuster drugs?
Rytary for Parkinson's and Unithroid for thyroid disorders are established and profitable, but neither is blockbuster-scale by industry standards. They drive Specialty margins substantially above Generics but cannot offset commodity price pressures alone.
Can Amneal pay down debt from operations?
Operating cash turned negative in the most recent quarter despite earnings, due to working capital timing and elevated capex. Meaningful debt reduction would require sustained free cash generation or asset sales—neither is assured under current leverage and market conditions.
Why did earnings swing so dramatically last year?
A severe trough quarter appears driven by working capital pressure and possible one-time charges. The subsequent recovery reflects Generics volume normalization and full-period Specialty acquisition contributions. Durability remains unproven and depends on sustained volume and pricing.
What is the AMRX stock price today?
The last price recorded for Amneal Pharmaceuticals, Inc. (AMRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AMRX price target?
The analyst consensus price target for Amneal Pharmaceuticals, Inc. (AMRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 75 from Financial Modeling Prep (FMP), 1 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com